Phase II Study of Bortezomib in Combination With Cyclophosphamide and Rituximab for Relapsed/Refractory Mantle Cell Lymphoma

Trial Profile

Phase II Study of Bortezomib in Combination With Cyclophosphamide and Rituximab for Relapsed/Refractory Mantle Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Filgrastim; Mesna; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Millennium
  • Most Recent Events

    • 25 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 16 Sep 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top